These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9448669)

  • 1. Treatment and outcomes in adolescents with schizophrenia.
    Schulz SC; Findling RL; Friedman L; Kenny JT; Wise AL
    J Clin Psychiatry; 1998; 59 Suppl 1():50-4; discussion 55-6. PubMed ID: 9448669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia.
    Ho BC; Andreasen NC; Nopoulos P; Arndt S; Magnotta V; Flaum M
    Arch Gen Psychiatry; 2003 Jun; 60(6):585-94. PubMed ID: 12796222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating clinical trial data: outcome measures.
    Conley RR
    J Clin Psychiatry; 2001; 62 Suppl 9():23-6; discussion 27-8. PubMed ID: 11379827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-episode schizophrenia. A window of opportunity for optimizing care and outcomes.
    Buckley PE; Evans D
    Postgrad Med; 2006 Sep; Spec No():5-19. PubMed ID: 17128657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals.
    Velakoulis D; Wood SJ; Wong MT; McGorry PD; Yung A; Phillips L; Smith D; Brewer W; Proffitt T; Desmond P; Pantelis C
    Arch Gen Psychiatry; 2006 Feb; 63(2):139-49. PubMed ID: 16461856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication.
    Snyder PJ; Jackson CE; Piskulic D; Olver J; Norman T; Maruff P
    Psychiatry Res; 2008 Sep; 160(3):316-26. PubMed ID: 18579217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic medications in children and adolescents.
    Findling RL; Grcevich SJ; Lopez I; Schulz SC
    J Clin Psychiatry; 1996; 57 Suppl 9():19-23. PubMed ID: 8823346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of progressive cortical gray matter loss in childhood-onset schizophrenia with that in childhood-onset atypical psychoses.
    Gogtay N; Sporn A; Clasen LS; Nugent TF; Greenstein D; Nicolson R; Giedd JN; Lenane M; Gochman P; Evans A; Rapoport JL
    Arch Gen Psychiatry; 2004 Jan; 61(1):17-22. PubMed ID: 14706940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
    Kasper S
    J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment.
    Altamura AC; Bobo WV; Meltzer HY
    Int Clin Psychopharmacol; 2007 Sep; 22(5):249-67. PubMed ID: 17690594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meeting everyday challenges: antipsychotic therapy in the real world.
    Gorwood P
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S156-62. PubMed ID: 16872807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research and treatment strategies in first-episode psychoses. The Pittsburgh experience.
    Keshavan MS; Schooler NR; Sweeney JA; Haas GL; Pettegrew JW
    Br J Psychiatry Suppl; 1998; 172(33):60-5. PubMed ID: 9764128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 16. Heterogeneity of treatment effects in schizophrenia.
    Stroup TS
    Am J Med; 2007 Apr; 120(4 Suppl 1):S26-31. PubMed ID: 17403379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Childhood and adolescent-onset schizophrenia: new information and definitions].
    Amitai M; Sever Y; Weizman A; Zalsman G
    Harefuah; 2012 Sep; 151(9):550-3, 554. PubMed ID: 23367752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurologic comorbidities in schizophrenia.
    Nasrallah HA
    J Clin Psychiatry; 2005; 66 Suppl 6():34-46. PubMed ID: 16107182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychologic functioning and structural MRI of the brain in patients with schizophrenia.
    Premkumar P; Sharma T
    Expert Rev Neurother; 2005 Jan; 5(1):85-94. PubMed ID: 15853478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome in schizophrenia: beyond symptom reduction.
    Meltzer HY
    J Clin Psychiatry; 1999; 60 Suppl 3():3-7; discussion 8. PubMed ID: 10073370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.